Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Dec 31, 2024
Revenue increased during the quarter and also rose compared with both the prior quarter and the same quarter a year ago. The sequential and year-over-year gains highlight consistent growth.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue increased during the quarter and also rose compared with both the prior quarter and the same quarter a year ago. The sequential and year-over-year gains highlight consistent growth.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.9B
Revenue reported for this quarter.
Quarter-over-quarter
+5.1%
Change from the immediately preceding quarter.
Year-over-year
+15.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$11B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $2.7B | +13.3% |
| Jun 30, 2024 | $2.6B | +6.1% |
| Sep 30, 2024 | $2.8B | +11.6% |
| Dec 31, 2024 | $2.9B | +15.7% |
Revenue performance
The quarter's revenue was higher than the immediately preceding quarter, continuing an upward trajectory from earlier periods.
Quarterly comparison
Compared with the same quarter one year earlier, revenue was higher in the current period. The year-over-year increase was more pronounced than the sequential gain.
What to watch
The Company used cash in operating activities for the full fiscal year, largely due to an acquisition payment, which may affect near-term liquidity.